文献一覧: 一般社団法人日本臨床薬理学会 (出版者)

4 0 0 0 OA 3.患者にとっての臨床試験と情報公開

著者: 中澤幾子
出版者: 一般社団法人日本臨床薬理学会
雑誌: 臨床薬理 (ISSN:03881601)
巻号頁・発行日: vol.42, no.4, pp.263-264, 2011 (Released:2011-10-03)

2018-12-22 19:52:53
4 + 2 Twitter

4 0 0 0 OA アスピリンの剤形に関連して

著者: 永井恒司
出版者: 一般社団法人日本臨床薬理学会
雑誌: 臨床薬理 (ISSN:03881601)
巻号頁・発行日: vol.2, no.2, pp.189-195, 1971-04-30 (Released:2010-06-28)
参考文献数: 22

2017-02-22 11:08:40
4 + 2 Twitter

3 0 0 0 OA 本態性高血圧に対するアムロジピンとベニジピンの効果の比較

著者: 柴田仁太郎倉本敦夫須藤要一田中由樹子
出版者: 一般社団法人日本臨床薬理学会
雑誌: 臨床薬理 (ISSN:03881601)
巻号頁・発行日: vol.31, no.2, pp.377-378, 2000-03-31 (Released:2010-06-28)

2023-06-30 10:21:47
1 知恵袋
2 + 0 Twitter

3 0 0 0 OA ピルジカイニドの血液透析による除去

著者: 林正博江修博金井隆之冨田昌孝松原仁志井上幸一長谷川武志瀬在義則
出版者: 一般社団法人日本臨床薬理学会
雑誌: 臨床薬理 (ISSN:03881601)
巻号頁・発行日: vol.27, no.1, pp.145-146, 1996-03-31 (Released:2010-06-28)
参考文献数: 3

2023-03-03 16:06:14
3 + 10 Twitter

3 0 0 0 OA 4.抗がん薬の治験について ―抗がん薬の医薬品開発―

著者: 安藤雄一村崎由佳
出版者: 一般社団法人日本臨床薬理学会
雑誌: 臨床薬理 (ISSN:03881601)
巻号頁・発行日: vol.47, no.2, pp.68-73, 2016-03-31 (Released:2016-04-15)

2022-02-17 14:51:53
3 + 9 Twitter

3 0 0 0 OA 6.薬物間相互作用の網羅的予測とマネージメント

著者: 樋坂章博
出版者: 一般社団法人日本臨床薬理学会
雑誌: 臨床薬理 (ISSN:03881601)
巻号頁・発行日: vol.44, no.6, pp.495-500, 2013-11-30 (Released:2013-12-20)
参考文献数: 9

2021-12-10 15:24:25
3 + 1 Twitter

3 0 0 0 OA 低圧低酸素環境下で喫煙習慣が低酸素耐性に及ぼす影響

著者: 米田郁雄長田博西尾栄助渡邊康裕
出版者: 一般社団法人日本臨床薬理学会
雑誌: 臨床薬理 (ISSN:03881601)
巻号頁・発行日: vol.29, no.1-2, pp.135-136, 1998-03-31 (Released:2010-06-28)
参考文献数: 1

2021-09-02 09:33:15
3 + 0 Twitter

3 0 0 0 OA MRSA除菌のためのカテキン吸入療法の検討

著者: 岡部浩典西尾信一郎山田浩大橋寿彦清水貴子渥美哲至村田吏江子夏目有希子大貫よし子青島しおり熊谷富子野沢りかこ尾澤法代原征彦小菅和仁渡邊裕司大橋京一
出版者: 一般社団法人日本臨床薬理学会
雑誌: 臨床薬理 (ISSN:03881601)
巻号頁・発行日: vol.32, no.2, pp.293S-294S, 2001-03-31 (Released:2010-06-28)
参考文献数: 5

2021-02-09 07:17:13
3 + 3 Twitter

3 0 0 0 OA アルコールとタバコ, カフェイン飲料との相互関係

著者: 羽賀道信清野忠紀
出版者: 一般社団法人日本臨床薬理学会
雑誌: 臨床薬理 (ISSN:03881601)
巻号頁・発行日: vol.8, no.3, pp.365-370, 1977-09-30 (Released:2010-06-28)
参考文献数: 10

2021-01-09 01:57:36
3 + 2 Twitter

3 0 0 0 OA ニフェジピンの薬物動態に及ぼすクレメジン投与タイミングの影響

著者: 桑谷圭二小手川勤堤喜美子織田麻奈美今井浩光奥平敏章中野重行
出版者: 一般社団法人日本臨床薬理学会
雑誌: 臨床薬理 (ISSN:03881601)
巻号頁・発行日: vol.34, no.2, pp.265S-266S, 2003-03-31 (Released:2010-06-28)
参考文献数: 2
被引用文献数: 1

2020-08-25 23:28:50
3 + 5 Twitter

3 0 0 0 OA ケフラールによるアナフィラキシーショックの発生率について

著者: 森久美子中井かをり浜六郎橋本則男黒田道代
出版者: 一般社団法人日本臨床薬理学会
雑誌: 臨床薬理 (ISSN:03881601)
巻号頁・発行日: vol.19, no.1, pp.173-174, 1988-03-31 (Released:2010-06-28)
参考文献数: 2

2020-01-14 20:23:57
3 + 5 Twitter

3 0 0 0 パーキンソン病患者の治療薬と自動車運転状況 : 重大自動車事故と抗パーキンソン薬との関係について

著者: 安藤利奈山崎知恵子岩城寛尚辻井智明矢部勇人西川典子永井将弘野元正弘
出版者: 一般社団法人日本臨床薬理学会
雑誌: 臨床薬理 (ISSN:03881601)
巻号頁・発行日: vol.48, no.5, pp.167-171, 2017-09-30 (Released:2017-10-28)
参考文献数: 11
被引用文献数: 2

Parkinson's disease (PD) causes motor impairment, but motor dysfunction can be improved by treatment. However, the package inserts of PD therapeutic drugs state “do not drive a car” as an important precaution in Japan. In addition, the package insert of non-ergot dopamine agonist (DA) states specifically “do not drive a car or operate a machine” as a warning because non-ergot DA causes sudden sleepiness and somnolence. On the other hand, driving is a very important means of transportation for daily living and work. Even though doctors explain at the clinic that the patients should not drive while on medications, many patients are forced to drive in everyday life. In addition, somnolence and sudden sleepiness differ among individuals. Therefore, doctors are confused about instructing patients to refrain from driving. We investigated the relation between non-ergot DA and driving situation in PD patients, which is a serious issue in the clinical setting. All 362 PD patients who visited our offices were interviewed regarding their driving situation, and detailed medications and car accidents were examine in 154 patients who continued driving a car or stopped driving after the onset of disease. In the investigation of medications, 51 patients were taking non-ergot DA, 36 patients (70.6%) of whom continued to drive. In addition, 20 of 154 patients had serious car accidents, but only six of the accidents were associated with somnolence and sudden sleepiness. In the examination of medications at the time of accident, there was no difference between non-ergot DA and other medications. These results suggest that upon receiving instructions from healthcare professionals, PD patients drive while making appropriate judgment about medication-induced somnolence. However, in this study, the number of patients who experienced serious car accidents was small, and the numbers of patients taking ergot DA and non-ergot DA were limited. Further larger scale study is required to confirm the findings. Preparation of guidelines related to instructions on taking PD medications is necessary, which include medication taking during holidays, consideration of the occurrence of sudden sleepiness and somnolence, and judgement of whether to continue driving.

2019-10-19 12:29:47
3 + 1 Twitter

3 0 0 0 OA 4.臨床研究における観察研究とランダム化比較試験

著者: 名郷直樹
出版者: 一般社団法人日本臨床薬理学会
雑誌: 臨床薬理 (ISSN:03881601)
巻号頁・発行日: vol.40, no.3, pp.117S-118S, 2009 (Released:2009-08-12)
参考文献数: 14

2019-07-21 11:47:03
3 + 3 Twitter

3 0 0 0 OA 4.プラセボの効果 ―特にパーキンソン病における効果について―

著者: 三輪英人
出版者: 一般社団法人日本臨床薬理学会
雑誌: 臨床薬理 (ISSN:03881601)
巻号頁・発行日: vol.40, no.4, pp.145-150, 2009 (Released:2009-10-15)
参考文献数: 17

The placebo effect can be observed in various medical conditions, and has been documented by randomized placebo-controlled drug studies. One of the best examples is the placebo effect in Parkinson's disease (PD). The placebo effect is observable not only in drug trials but also with surgical therapies, such as deep brain stimulation, fetal tissue transplantation, and infusion therapy of a neurotrophic factor. A recent study using positron emission tomography (PET) with raclopride demonstrated that the release of endogeneous dopamine in the dorsal striatum mediates the placebo effect in PD, suggesting that the placebo effectiveness is achieved by endogenous dopamine supplementation. Although the detailed pathophysiological mechanism underlying the placebo effect is unclear, the placebo effect has been explained by two mechanisms: the conditioning theory (pavlovian conditioning) and the cognitive or expectancy theory (expectation of clinical improvement). Speculatively, it may be that the placebo effect in PD is related more to cognitive mechanisms. Numerous studies have suggested a functional relationship between dopamine and the reward system. Understanding the placebo effect is important for designing clinical trials and interpreting their results.